Economic Evaluations of First-Line Chemotherapy Regimens for Pancreatic Cancer: A Critical Review
- 14 September 2016
- journal article
- review article
- Published by Springer Nature in PharmacoEconomics
- Vol. 35 (1) , 83-95
Abstract
Effect sizes of efficacy of first-line treatments for (metastatic) pancreas cancer are constrained, underscoring the need for evaluations of the efficacy-to-cost relationship. We critically review economic evaluations of first-line chemotherapy regimens for pancreatic cancer since the 1997 introduction of gemcitabine. We searched PubMed/MEDLINE and EMBASE (1997–2015), and the websites of health technology assessment agencies. Two authors independently reviewed economic studies for eligibility in this review; evaluated peer-reviewed, journal-published studies in terms of the Drummond Checklist; and critiqued the technical and scientific merit of all studies. Sixteen pharmacoeconomic evaluations were included: ten published in nine peer-reviewed journals and six on three websites. Six were on single-agent therapies and ten on combination therapies. Analyses conducted included cost-effectiveness (three studies), cost-utility (one study), or combined cost-effectiveness and cost-utility (12 studies). Studies diverged in results, mainly because of different assumptions, methods, inputs, and country-specific guidelines. The two most recent regimens, nanoparticle albumin-bound paclitaxel plus gemcitabine (NAB-P + GEM) and the combination of fluorouracil, oxaliplatin, leucovorin, and irinotecan (FOLFIRINOX), were evaluated in an indirect comparison, yielding a statistically similar benefit in overall survival but superior progression-free survival for FOLFIRINOX. NAB-P + GEM showed greater economic benefit over FOLFIRINOX. In conclusion, the divergence in results observed across studies is attributable to economic drivers that are specific to countries and their healthcare (financing) systems. No recommendations regarding the relative economic benefit of treatment regimens, general or country-specific, are made as the purpose of pharmacoeconomic analysis is to inform policy decision-making and clinical practice, not set policy or define clinical practice.Keywords
This publication has 38 references indexed in Scilit:
- Cost-Effectiveness of Systemic Therapies for Metastatic Pancreatic CancerCurrent Oncology, 2013
- Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemiaThe European Journal of Health Economics, 2012
- Does Health-Related Quality of Life Improve for Advanced Pancreatic Cancer Patients Who Respond to Gemcitabine? Analysis of a Randomized Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)Journal of Pain and Symptom Management, 2012
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinomaJournal of Hematology & Oncology, 2011
- Estimating the Power of Indirect Comparisons: A Simulation StudyPLOS ONE, 2011
- Health state utilities for non small cell lung cancerHealth and Quality of Life Outcomes, 2008
- Health state utilities for metastatic breast cancerBritish Journal of Cancer, 2006
- Reconciliation of Economic Concerns and Health PolicyPharmacoEconomics, 2004
- Treatment of Locally Advanced Pancreatic Carcinoma in SwedenPharmacoEconomics, 1999